Valuation: Eisai Co., Ltd.

Market Cap 1,256B 7.73B 6.77B 6.26B 5.76B 10.86B 745B 11.04B 74.85B 29.34B 365B 29.01B 28.38B P/E 2027 *
22.6x
P/E 2028 * 19.2x
Enterprise Value 1,165B 7.16B 6.28B 5.8B 5.34B 10.07B 691B 10.23B 69.41B 27.21B 338B 26.9B 26.32B EV / Sales 2027 *
1.3x
EV / Sales 2028 * 1.24x
Free-Float
94.55%
Yield 2027 *
3.6%
Yield 2028 * 3.64%
15/07 Bioarctic AB Partner Eisai Presents Real-World Leader Study Results for Leqembi in Early Alzheimer?S Disease CI
15/07 Eisai Co., Ltd. and Biogen Inc. Present Real-World LEADER Study Results For LEQEMBI At AAIC 2026 CI
14/07 Biogen's Alzheimer's drug lowers toxic protein, but results were mixed RE
14/07 FDA Approves Eisai, Biogen's LEQEMBI Injection for Early Alzheimer's MT
14/07 Eisai Co., Ltd. And Biogen Inc. Receive FDA Approval For LEQEMBI IQLIK Subcutaneous Injection As Initiation Dose For Early Alzheimer?s Disease CI
14/07 Eisai, Biogen Get FDA Approval for Treatment for Early Alzheimer's Disease DJ
14/07 FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug RE
13/07 Eisai Co., Ltd. Presents Latest Findings On Etalanetug Showing Reduction In Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-Tau243 at Alzheimer's Association International Conference 2026 CI
13/07 BioArctic AB Announces FDA Approval Of Leqembi Iqlik (Lecanemab-Irmb) Subcutaneous Injection As Starting Dose For Early Alzheimer's Disease CI
13/07 Eisai Co., Ltd. And Biogen Inc. Present Clinical Data Supporting Leqembi Subcutaneous Autoinjector Efficacy And Safety Comparable To Intravenous Formulation In Early Alzheimer's Disease CI
02/07 Eisai Co., Ltd.'s Acceptance of Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant for Evaluation by the United Kingdom?s Medicines and Healthcare Products Regulatory Agency CI
30/06 Eisai Present New Clinical And Real-World Evidence On Lecanemab At AAIC Conference CI
30/06 Eisai Co Ltd Showcases Alzheimer?s Disease Portfolio With Over 50 Presentations At Alzheimer?s Association International Conference 2026 CI
1 day+0.72%
1 week+2.42%
Current month+8.81%
1 month+14.89%
3 months-7.74%
6 months+0.54%
Current year-3.82%
1 week 4,238
Extreme 4238
4,529
1 month 3,822
Extreme 3822
4,529
Current year 3,660
Extreme 3660
5,243
1 year 3,660
Extreme 3660
5,349
3 years 3,463
Extreme 3463
9,614
5 years 3,463
Extreme 3463
11,250
10 years 3,463
Extreme 3463
12,765
Manager TitleAgeSince
Chief Executive Officer 78 01/06/2003
Director of Finance/CFO 49 01/01/2026
Chief Tech/Sci/R&D Officer 48 01/04/2025
Director TitleAgeSince
Director/Board Member 78 01/06/1983
Director/Board Member 66 14/06/2024
Director/Board Member 67 01/06/2025
Change 5-day change 1-year change 3-year change Capi.($)
+0.72%+2.42%+16.96%-50.38% 7.73B
-2.73%-2.96%+48.62%+147.27% 1,023B
-1.67%-3.47%+52.00%+47.77% 599B
-0.44%+2.17%+33.88%+78.20% 448B
-0.27%+1.41%+29.73%+20.76% 326B
+2.77%+3.71%+38.68%+39.10% 278B
+0.51%+0.71%+21.70%+15.62% 258B
-0.90%+1.61%-20.94%-41.43% 222B
-0.58%+1.03%+23.55%+56.14% 197B
-0.80%+1.38%+23.09%+66.64% 165B
Average +0.25%+0.01%+26.73%+37.97% 352.28B
Weighted average by Cap. +0.31%-1.17%+35.77%+70.51%

Financials

2027 *2028 *
Net sales 894B 5.5B 4.82B 4.46B 4.1B 7.73B 530B 7.86B 53.29B 20.89B 260B 20.65B 20.2B 947B 5.83B 5.11B 4.72B 4.34B 8.19B 562B 8.32B 56.44B 22.13B 275B 21.88B 21.4B
Net income 56.13B 345M 303M 280M 257M 486M 33.3B 493M 3.35B 1.31B 16.29B 1.3B 1.27B 65.84B 405M 355M 328M 302M 569M 39.05B 579M 3.92B 1.54B 19.11B 1.52B 1.49B
Net Debt -91.31B -562M -492M -455M -419M -790M -54.17B -802M -5.44B -2.13B -26.5B -2.11B -2.06B -82.35B -507M -444M -410M -377M -712M -48.85B -724M -4.91B -1.92B -23.9B -1.9B -1.86B
Logo Eisai Co., Ltd.
Eisai Co Ltd is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Russia, Oceania), Asia and Latin America (Korea, Taiwan, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.
Employees
10,543
Date Price Change Volume
21/07/26 JPY 4,482.00 +0.72% 1,884,600
17/07/26 JPY 4,450.00 +2.58% 1,934,700
16/07/26 JPY 4,338.00 +1.93% 1,343,700
15/07/26 JPY 4,256.00 -2.74% 1,765,700
14/07/26 JPY 4,376.00 +3.13% 2,570,300
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
4,450.00JPY
Average target price
4,482.14JPY
Spread / Average Target
+0.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4523 Stock